Search results
Author(s):
Harishchandra Amadoru
,
Rajitha Yasela De Silva
,
Kariyawasam Don Nandasiri Weerasinghe
,
et al
Added:
1 year ago
Author(s):
Vikas Kadiyala
,
Khung Keong Yeo
Added:
1 year ago
The QUADRIC Study
Author(s):
Wei Juan Lim
,
David Yong Tat Wei
,
Yuen Han Lim
,
et al
Added:
1 month ago
Article
Author(s):
Ajinkya Mahorkar
,
Virag Mahorkar
,
Uday Mahorkar
,
et al
Added:
1 month ago
ESC 24: The OCCUPI Trial
Author(s):
Byeong-Keuk Kim
Added:
8 months ago
Video
Author(s):
Billy Joseph David
,
Reynald Evan R Tugade
,
Ferdinand Jr Gerodias
Added:
1 year ago
Author(s):
David Erlinge
Added:
6 months ago
TCT Conference 2024 - Significant reduction in TLF and TVF and flattening of event curves after 6 months in favour of DynamX Bioadaptor.Dr David Erlinge (Skane University Hospital, Lund, SE) joins us onsite at TCT Conference to discuss the findings from INFINITY-SWEDEHEART (NCT04562805).INFINITY-SWEDEHEART is a prospective, multicenter, randomized registry-based clinical trial, where patients…
View more
Author(s):
Nicolas M Van Mieghem
,
Joost Daemen
Added:
9 months ago
Which interventional cardiology studies will have the greatest impact at ESC 2024?Leading experts Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) offer an exclusive preview of the most anticipated hot line studies set to be unveiled at ESC Congress 2024. Get their in-depth analysis of the studies and gain invaluable insights ahead of the curve.ESC Congress…
View more
Author(s):
Naoki Hayakawa
Added:
2 months ago
LINC 2025 - Three-year outcomes of drug-coated balloon (DCB) treatment for femoropopliteal (FP) chronic total occlusive (CTO) lesions show low patency rates in patents with multiple independent risk factors for patency loss. However, patients without risk factors achieved acceptable patency rates and clinical outcomes of freedom from clinically driven target lesion revascularization, reoclussion…
View more
Author(s):
Khung Keong Yeo
,
Ryuji Fukazawa
,
Mamoru Ayusawa
,
et al
Added:
1 year ago